Our approach to R&D


Driven by science, united by science

Our ambition is to transform the lives of patients with improved outcomes and a better quality of life, through more effective treatment and prevention, ultimately working toward a cure for some of the world’s most complex diseases.

We have a unique R&D culture where people with curious minds are inspired to think creatively. At the same time, we are harnessing data and technology to fast-forward the pace of our science. It is a culture where people are able to work seamlessly and inclusively together, where all doors are open, talent and diversity are celebrated, and every voice is heard. In addition, we are always learning from people who live with the diseases our medicines treat so we can understand their needs and make sure that great science born in the lab can make a real difference to their lives.

It’s by creating and sustaining this culture that we are able to help unlock the power of what science can do.

 







Focusing on quality, not quantity


Our drug discovery and development is guided by our 5R Framework, which champions quality over quantity, and has helped transform the culture of R&D and our business.

Over a 5-year period, it has enabled us to achieve a more than four-fold improvement in the proportion of pipeline molecules advancing from pre-clinical investigation to completion of

Phase III clinical trials from 4% -19%*.

* (Morgan et al., (2018) Nature Reviews Drug Discovery)

 





Transformative science


We are never complacent about scientific discovery and development, always pushing our R&D productivity, searching for new knowledge and the next breakthrough.

Guided by our ‘Growth Through Innovation’ strategy, we are committed to investing in four areas, which will help us in our aspiration to create the greatest and swiftest impact on disease:






Two organisations. One aim


We have two therapy-focused R&D organisations who lead all our work, from discovery through to late-stage development. These are Oncology R&D, which is focused on cancer, and BioPharmaceuticals R&D which is focused on Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology, and opportunistically, Neuroscience and Microbial Science.

The two organisations work both independently and together, sharing Functions specialising in key scientific capabilities from medicinal chemistry to biometrics, patient safety to data science and artificial intelligence (AI), and clinical innovation to device technology. All of which help us accelerate discovery and development in our efforts to bring new medicines to patients.

Our R&D groups are unified in their approach, and united in their purpose to deliver life-changing medicines to people who need them most.





Keeping doors and our minds open



We know that however innovative our science is, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone. To address all the issues facing healthcare and achieve the scientific breakthroughs we aspire to, we need to work together, collaborating among ourselves and with others, bringing the best talent to bear on the toughest problems.

As a business, our teams are leading the way in creating open research environments that go beyond the usual collaborative models, with academia, biotech companies, industry peers, healthcare systems and governments. We have over 1,400 active partnerships and believe it to be a powerful source of transformational potential.

Our Open Innovation programme is designed to offer a permeable research environment where scientists both inside and outside of AstraZeneca can share their ideas and collaborate on projects.




STEM – Empowering the next generation of science leaders


Supporting STEM education programmes is a core component of our sustainability strategy.  We are committed to empowering the next generation of scientific leaders and to inspiring students across genders, races and geographies to consider STEM careers in healthcare.





Making our science sustainable


We are a scientifically driven business with a strong global presence and as such, believe that we have a duty of care to help improve people’s health and do as much as we can to contribute to the health of the planet.

Our approach to sustainability is built around three pillars:


You may also like


Join us

If you believe in the power of what science can do, join us in our endeavour to push the boundaries of science to deliver life-changing medicines.


Collaborate with us

We know that however innovative our science, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone.